Evaluation of serum levels of p53 in hepatocellular carcinoma in Egypt

Abstract Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-induced death. Somatic mutation of the p53 gene is the most common genetic abnormality so far described in human cancer and there is evidence that supports a high level of p53 alterations in HCC. The aim of this study was to investigate serum levels of p53 in Egyptian patients with HCC, and its relation to other prognostic factors such as tumor grade, α-fetoprotein (AFP), and liver function tests in an attempt to clarify their significance in the pathogenesis of the disease. Liver function tests were carried out and AFP and p53 levels were measured for all individuals studied. Our results show that detection of p53 increased the frequency of HCC prediction from 79.5% to 86.3%. Moreover, significant positive correlation between p53 and tumor size (cm) for tumor grade II and III was identified. In conclusion, serum concentration of p53 protein may be a convenient and useful non-invasive screening test for prediction of HCC.

[1]  K. Meyer,et al.  Transcriptional Repression of p53 Promoter by Hepatitis C Virus Core Protein* , 1997, The Journal of Biological Chemistry.

[2]  Y. Jeng,et al.  High α‐fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: Significance of hepatitis virus infection, age, p53 and β‐catenin mutations , 2004 .

[3]  R. DeMatteo,et al.  Genes and viruses in hepatobiliary neoplasia. , 2000, Seminars in surgical oncology.

[4]  Kenzo Kobayashi,et al.  Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis , 1990, Hepatology.

[5]  L. Chiang,et al.  Involvement of p53, nuclear factor kappaB and Fas/Fas ligand in induction of apoptosis and cell cycle arrest by saikosaponin d in human hepatoma cell lines. , 2004, Cancer letters.

[6]  M. Torbenson,et al.  Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation , 2005, International journal of gastrointestinal cancer.

[7]  G. Chau,et al.  Evaluation of a simplified staging system for prognosis of hepatocellular carcinoma. , 1999, Journal of the Formosan Medical Association = Taiwan yi zhi.

[8]  M. Ikeda,et al.  Past exposure to hepatitis B virus as a risk factor for hepatocellular carcinoma in patients with chronic liver disease. , 1998, British Journal of Cancer.

[9]  N. Iizuka,et al.  Gene expression profile linked to p53 status in hepatitis C virus‐related hepatocellular carcinoma , 2003, FEBS letters.

[10]  C. Nguyen,et al.  Tumor‐suppressor p53 gene in hepatitis C and B virus‐associated human hepatocellular carcinoma , 1993, International journal of cancer.

[11]  L. Garrett,et al.  Low level amplification of c-sis and c-myc in a spontaneous osteosarcoma model. , 1990, Cancer letters.

[12]  Y. Jeng,et al.  High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. , 2004, International journal of cancer.

[13]  A. Bisceglie.  13 Hepatitis C and hepatocellular carcinoma , 2000 .

[14]  J. Pawlotsky.  Measuring hepatitis C viremia in clinical samples: Can we trust the assays? , 1997, Hepatology.

[15]  H. Zentgraf,et al.  p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. , 1994, Oncogene.